India, Netherlands partner for vaccines development

Under the "Make in India" initiative, India and the Netherlands signed a memorandum of understanding enabling Bharat Immunologicals and Biologicals, a public-sector biotech under India's department of biotechnology, to develop a measles and rubella vaccine with the assistance of the Netherlands' government-based Translational Vaccinology. Bharat Immunologicals, established in 1989, aims at achieving self-sufficiency for India's production and supply of polio vaccines and other biologicals. The agreement is hoped to bring about large-scale production of the vaccine and others in India. More

Suggested Articles

BN will use its proprietary MVA-BN platform to develop a vaccine against three strains of the potentially deadly mosquito-borne virus.

BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.

The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.